VIPoma secondary prevention: Difference between revisions
Homa Najafi (talk | contribs) No edit summary |
m Bot: Removing from Primary care |
||
| Line 19: | Line 19: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
Latest revision as of 00:40, 30 July 2020
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of VIPoma secondary prevention |
|
Risk calculators and risk factors for VIPoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]
Overview
Effective measures for the secondary prevention of VIPoma include history and physical examination, serum VIP levels and indicated markers, and multi-phasic CT scan or MRI.
Secondary Prevention
Effective measures for the secondary prevention of VIPoma include:[1][2][3]
Note: These follow-up should be done every 3 to 12 months up to one year post resection and every 6 to 12 months thereafter.
References
- ↑ Kulke, Matthew H.; Benson, Al B.; Bergsland, Emily; Berlin, Jordan D.; Blaszkowsky, Lawrence S.; Choti, Michael A.; Clark, Orlo H.; Doherty, Gerard M.; Eason, James; Emerson, Lyska; Engstrom, Paul F.; Goldner, Whitney S.; Heslin, Martin J.; Kandeel, Fouad; Kunz, Pamela L.; Kuvshinoff, Boris W.; Moley, Jeffrey F.; Pillarisetty, Venu G.; Saltz, Leonard; Schteingart, David E.; Shah, Manisha H.; Shibata, Stephen; Strosberg, Jonathan R.; Vauthey, Jean-Nicolas; White, Rebekah; Yao, James C.; Freedman-Cass, Deborah A.; Dwyer, Mary A. (2012). "Neuroendocrine Tumors". Journal of the National Comprehensive Cancer Network. 10 (6): 724–764. doi:10.6004/jnccn.2012.0075. ISSN 1540-1405.
- ↑ Kunz, Pamela L.; Reidy-Lagunes, Diane; Anthony, Lowell B.; Bertino, Erin M.; Brendtro, Kari; Chan, Jennifer A.; Chen, Herbert; Jensen, Robert T.; Kim, Michelle Kang; Klimstra, David S.; Kulke, Matthew H.; Liu, Eric H.; Metz, David C.; Phan, Alexandria T.; Sippel, Rebecca S.; Strosberg, Jonathan R.; Yao, James C. (2013). "Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors". Pancreas. 42 (4): 557–577. doi:10.1097/MPA.0b013e31828e34a4. ISSN 0885-3177.
- ↑ Bourcier, Matthew E.; Vinik, Aaron I. (2013). "Sunitinib for the Treatment of Metastatic Paraganglioma and Vasoactive Intestinal Polypeptide-Producing Tumor (VIPoma)". Pancreas. 42 (2): 348–352. doi:10.1097/MPA.0b013e31825c53fa. ISSN 0885-3177.